Carlos Castrillon

Carlos Castrillon

Auto-generated profile, based on publicly available information

Carlos Castrillon

Department of Medicine, Emory University School of Medicine, Atlanta, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAnnabelle Gérard
Annabelle Gérard
AWAdam Woolfe
Adam Woolfe
GMGuillaume Mottet
Guillaume Mottet
MRMarcel Reichen
Marcel Reichen
CCCarlos Castrillon
Carlos Castrillon
CBColin Brenan
Colin Brenan

15 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PCPablo Canales-Herrerias
Pablo Canales-Herrerias
ECEtienne Crickx
Etienne Crickx
MBMatteo Broketa
Matteo Broketa
ASAurélien Sokal
Aurélien Sokal
GCGuilhem Chenon
Guilhem Chenon
PBPierre Bruhns
Pierre Bruhns
The major therapeutic goal for immune thrombocytopenic purpura (ITP) is to restore normal platelet counts using drugs to promote platelet production or by interfering with mechanisms responsible for platelet destruction. Eighty percent of patients with ITP possess anti–integrin αIIbβ3 IgG autoantibodies that cause platelet opsonization and phagocytosis. The spleen is considered the primary site of autoantibody production by autoreactive B cells and platelet destruction. The immediate failure in approximately 50% of patients to recover a normal platelet count after anti-CD20 rituximab-mediated B cell depletion and splenectomy suggests that autoreactive, rituximab-resistant, IgG-secreting B cells (IgG-SCs) reside in other anatomical compartments. We analyzed more than 3,300 single IgG-SCs from spleen, bone marrow, and/or blood of 27 patients with ITP, revealing high interindividual variability in affinity for αIIbβ3, with variations over 3 logs. IgG-SC dissemination and range of affinities were, however, similar for each patient. Longitudinal analysis of autoreactive IgG-SCs upon treatment with the anti-CD38 mAb daratumumab demonstrated variable outcomes, from complete remission to failure with persistence of high-affinity anti–αIIbβ3 IgG-SCs in the bone marrow. This study demonstrates the existence and dissemination of high-affinity autoreactive plasma cells in multiple anatomical compartments of patients with ITP that may cause the failure of current therapies.

22 March 2024 in Science Immunology
Verified
Journal Article
Closed access
TBTheo van Den Broek
Theo van Den Broek
KOKristine Oleinika
Kristine Oleinika
SRSiti Rahmayanti
Siti Rahmayanti
CCCarlos Castrillon
Carlos Castrillon
CPCees E. van der Poel
Cees E. van der Poel
MCMichael C. Carroll
Michael C. Carroll
In autoreactive germinal centers (GC) initiated by a single rogue B cell clone, wild-type B cells expand and give rise to clones that target other autoantigens, known as epitope spreading. The chronic, progressive nature of epitope spreading calls for early interventions to limit autoimmune pathologies, but the kinetics and molecular requirements for wild-type B cell invasion and participation in GC remain largely unknown. With parabiosis and adoptive transfer approaches in a murine model of systemic lupus erythematosus, we demonstrate that wild-type B cells join existing GCs rapidly, clonally expand, persist, and contribute to autoantibody production and diversification. The invasion of autoreactive GCs by wild-type B cells required TLR7, B cell receptor specificity, antigen presentation, and type I interferon signaling. The adoptive transfer model provides a tool for identifying early events in the breaking of B cell tolerance in autoimmunity.

7 April 2026 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
DZDanni Yi-Dan Zhu
Danni Yi-Dan Zhu
CCCarlos Castrillon
Carlos Castrillon
EAElliot Akama-Garren
Elliot Akama-Garren
MCMichael C. Carroll
Michael C. Carroll

14 November 2025 in Science Immunology
Verified
Journal Article
Closed access
DZDanni Y. Zhu
Danni Y. Zhu
DMDaniel P. Maurer
Daniel P. Maurer
CCCarlos Castrillon
Carlos Castrillon
YDYixiang Deng
Yixiang Deng
FMFaez A. N. Mohamed
Faez A. N. Mohamed
MCMichael C. Carroll
Michael C. Carroll
The extrafollicular (EF) B cell differentiation pathway has emerged as a prominent source of autoantibody-secreting cells (ASCs) in systemic lupus erythematosus (SLE). CD21 lo CD11c + B cells are associated with aging, infection, and autoimmunity. They are key contributors to EF ASCs, yet their developmental trajectory and receptor programming are unclear. To study EF mechanics of autoreactive B cells, we adoptively transferred naïve B cell populations into 564Igi mice, which act as an autoreactive host enriched for autoantigens and T cell help. Time-resolved analyses revealed a Toll-like receptor 7 (TLR7)–dependent early escape of peripheral tolerance and a pre–ASC division program. We identified naïve-derived CD21 lo cells as precursors of EF ASCs exhibiting elevated reliance on TLR7. Repertoire analysis delineated protoautoreactive B cell selection and receptor evolution toward self-reactivity. Continuous complement receptor 2 (CR2/CD21)–complement C3d and CD21–complement iC3b engagement triggered receptor down-regulation before proliferation. We reveal CD21 as an initiator of TLR7-dependent autoimmune EF proliferation and target for suppressing autoreactivity.

22 May 2020 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
AGAnnabelle Gérard
Annabelle Gérard
AWAdam Woolfe
Adam Woolfe
GMGuillaume Mottet
Guillaume Mottet
MRMarcel Reichen
Marcel Reichen
CCCarlos Castrillon
Carlos Castrillon
CBColin Brenan
Colin Brenan
An amendment to this paper has been published and can be accessed via a link at the top of the paper.